Synergistic Effect between Cisplatin and Sunitinib Malate on Human Urinary Bladder-Cancer Cell Lines
Figure 3
Combined effects of cisplatin (3, 6, and 13 μM) and sunitinib malate (1, 2, and 4 μM) on HT1376, T24, and 5637 urinary bladder-cancer cell lines viability, assessed by using the MTT assay. The data shown and bars represent the mean values ± SD (SD: standard deviation). versus untreated cells.
